Drug Type Antibody drug conjugate (ADC), Liposomal Drug |
Synonyms Antibody-conjugated Temozolomide liposomal nanoparticle (NanoValent), B7H3/Temozolomide nanoparticles, NV105 |
Target |
Action inhibitors |
Mechanism CD276 inhibitors(CD276 antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma Multiforme | Discovery | United States | 12 Oct 2022 |